NYSE:QGENLife Sciences
Qiagen’s New Ebola Assays Test Investor Views On Undervalued Shares
Qiagen launched new digital PCR assays for Bundibugyo ebolavirus surveillance, expanding its infectious disease research tools.
The assays are research use only and are designed to help laboratories and public health teams track the emerging outbreak.
The release highlights Qiagen's focus on rapid support for global outbreak response workflows.
For investors watching NYSE:QGEN, this move comes as the stock trades at $36.59. The share price is up 4.0% over the past week and 8.9% over the...